- Home
- CGEM vs PRCT Comparison
CGEM vs PRCT Comparison
Compare CGEM & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | PRCT |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CGEM | PRCT |
|---|---|---|
| Price | $20.77 | $19.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $30.13 | ★ $35.44 |
| AVG Volume (30 Days) | 750.3K | ★ 1.1M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | $5.20 | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $5.68 | $16.67 |
| 52 Week High | $23.19 | $39.99 |
Technical Indicators
Market Signals| Indicator | CGEM | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 41.85 |
| Support Level | $11.87 | $16.89 |
| Resistance Level | $23.19 | $29.27 |
| Average True Range (ATR) | 0.96 | 1.11 |
| MACD | -0.26 | -0.27 |
| Stochastic Oscillator | 51.40 | 6.52 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.